Sign In

Login

Password

Forgot Password ? Sign Up

كيتوتيفين (Arabic Wikipedia)

Analysis of information sources in references of the Wikipedia article "كيتوتيفين" in Arabic language version.

refsWebsite
Global rank Arabic rank
12nih.gov
4th place
6th place
9doi.org
2nd place
5th place
5web.archive.org
1st place
1st place
3semanticscholar.org
11th place
86th place
1springer.com
274th place
307th place
1ukmasto.org
low place
low place

doi.org

  • Grant SM، Goa KL، Fitton A، Sorkin EM (سبتمبر 1990). "Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders". Drugs. ج. 40 ع. 3: 412–448. DOI:10.2165/00003495-199040030-00006. PMID:2226222. S2CID:242916740.
  • Dou XY، Zhang W (2023). "Topical ketotifen treatment for allergic conjunctivitis: a systematic review and Meta-analysis". Int J Ophthalmol. ج. 16 ع. 2: 286–292. DOI:10.18240/ijo.2023.02.17. PMC:9922628. PMID:36816214.
  • Shawky RM، Seifeldin NS (2015). "The relation between antihistamine medication during early pregnancy & birth defects". Egyptian Journal of Medical Human Genetics. ج. 16 ع. 4: 287–90. DOI:10.1016/j.ejmhg.2015.04.003.
  • Zuberbier T (يناير 2012). "A Summary of the New International EAACI/GA(2)LEN/EDF/WAO Guidelines in Urticaria". The World Allergy Organization Journal. ج. 5 ع. Suppl 1: S1–S5. DOI:10.1186/1939-4551-5-S1-S1. PMC:3488932. PMID:23282889.
  • Zuberbier T، Asero R، Bindslev-Jensen C، Walter Canonica G، Church MK، Giménez-Arnau AM، Grattan CE، Kapp A، Maurer M، Merk HF، Rogala B، Saini S، Sánchez-Borges M، Schmid-Grendelmeier P، Schünemann H، Staubach P، Vena GA، Wedi B (أكتوبر 2009). "EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria". Allergy. ج. 64 ع. 10: 1427–1443. DOI:10.1111/j.1398-9995.2009.02178.x. PMID:19772513. S2CID:14587946.
  • Frieri M (يونيو 2018). "Mast Cell Activation Syndrome". Clin Rev Allergy Immunol. ج. 54 ع. 3: 353–365. DOI:10.1007/s12016-015-8487-6. PMID:25944644. S2CID:5723622.
  • Markham A، Goa KL (1996). "Ketotifen". Clinical Immunotherapeutics. ج. 5 ع. 5: 400–411. DOI:10.1007/BF03259336. مؤرشف من الأصل في 2024-08-06. اطلع عليه بتاريخ 2024-07-17.
  • MacDonald G (1982). "An Overview of Ketotifen". Chest. ج. 82 ع. 1 Suppl: 30s–32s. DOI:10.1378/chest.82.1.30S. PMID:6806019. مؤرشف من الأصل في 2024-07-17.
  • Zhu TH، Zou G، Ding SJ، Li TT، Zhu LB، Wang JZ، Yao YX، Zhang XM (2019). "Mast cell stabilizer ketotifen reduces hyperalgesia in a rodent model of surgically induced endometriosis". J Pain Res. ج. 12: 1359–1369. DOI:10.2147/JPR.S195909. PMC:6500880. PMID:31118754. Ketotifen has a stronger effect on stabilizing MCs than sodium cromoglycate. This drug has antihistamine activity and is also a functional leukotriene antagonist

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Grant SM، Goa KL، Fitton A، Sorkin EM (سبتمبر 1990). "Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders". Drugs. ج. 40 ع. 3: 412–448. DOI:10.2165/00003495-199040030-00006. PMID:2226222. S2CID:242916740.
  • Dou XY، Zhang W (2023). "Topical ketotifen treatment for allergic conjunctivitis: a systematic review and Meta-analysis". Int J Ophthalmol. ج. 16 ع. 2: 286–292. DOI:10.18240/ijo.2023.02.17. PMC:9922628. PMID:36816214.
  • Zuberbier T (يناير 2012). "A Summary of the New International EAACI/GA(2)LEN/EDF/WAO Guidelines in Urticaria". The World Allergy Organization Journal. ج. 5 ع. Suppl 1: S1–S5. DOI:10.1186/1939-4551-5-S1-S1. PMC:3488932. PMID:23282889.
  • Zuberbier T، Asero R، Bindslev-Jensen C، Walter Canonica G، Church MK، Giménez-Arnau AM، Grattan CE، Kapp A، Maurer M، Merk HF، Rogala B، Saini S، Sánchez-Borges M، Schmid-Grendelmeier P، Schünemann H، Staubach P، Vena GA، Wedi B (أكتوبر 2009). "EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria". Allergy. ج. 64 ع. 10: 1427–1443. DOI:10.1111/j.1398-9995.2009.02178.x. PMID:19772513. S2CID:14587946.
  • Frieri M (يونيو 2018). "Mast Cell Activation Syndrome". Clin Rev Allergy Immunol. ج. 54 ع. 3: 353–365. DOI:10.1007/s12016-015-8487-6. PMID:25944644. S2CID:5723622.
  • MacDonald G (1982). "An Overview of Ketotifen". Chest. ج. 82 ع. 1 Suppl: 30s–32s. DOI:10.1378/chest.82.1.30S. PMID:6806019. مؤرشف من الأصل في 2024-07-17.
  • Zhu TH، Zou G، Ding SJ، Li TT، Zhu LB، Wang JZ، Yao YX، Zhang XM (2019). "Mast cell stabilizer ketotifen reduces hyperalgesia in a rodent model of surgically induced endometriosis". J Pain Res. ج. 12: 1359–1369. DOI:10.2147/JPR.S195909. PMC:6500880. PMID:31118754. Ketotifen has a stronger effect on stabilizing MCs than sodium cromoglycate. This drug has antihistamine activity and is also a functional leukotriene antagonist

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

semanticscholar.org

api.semanticscholar.org

  • Grant SM، Goa KL، Fitton A، Sorkin EM (سبتمبر 1990). "Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders". Drugs. ج. 40 ع. 3: 412–448. DOI:10.2165/00003495-199040030-00006. PMID:2226222. S2CID:242916740.
  • Zuberbier T، Asero R، Bindslev-Jensen C، Walter Canonica G، Church MK، Giménez-Arnau AM، Grattan CE، Kapp A، Maurer M، Merk HF، Rogala B، Saini S، Sánchez-Borges M، Schmid-Grendelmeier P، Schünemann H، Staubach P، Vena GA، Wedi B (أكتوبر 2009). "EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria". Allergy. ج. 64 ع. 10: 1427–1443. DOI:10.1111/j.1398-9995.2009.02178.x. PMID:19772513. S2CID:14587946.
  • Frieri M (يونيو 2018). "Mast Cell Activation Syndrome". Clin Rev Allergy Immunol. ج. 54 ع. 3: 353–365. DOI:10.1007/s12016-015-8487-6. PMID:25944644. S2CID:5723622.

springer.com

link.springer.com

ukmasto.org

web.archive.org